AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10807190 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen (150 mg lamivudine twice daily, 600 mg zidovudine daily, and a protease inhibitor)
Number of subjects: 223
Study 10807190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet regimen
Number of subjects: 223
Study 10807190 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 223
Study 8794812 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation (estradiol valerate, 2 mg daily, n = 6)
Number of subjects: 11
Study 8794812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 11
Study 1536438 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous blood (group 2, n = 14)
Number of subjects: 42
Study 1536438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra- and postoperative autologous fresh frozen plasma (FFP) (group 3, n = 16)
Number of subjects: 42
Study 1536438 — intervention group
Group type: COMPARATOR
Intervention: Homologous blood (control group, group 1, n = 12)
Number of subjects: 42
Study 6465489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release morphine 20 mg
Number of subjects: 0
Study 6465489 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine 10 mg
Number of subjects: 0
Study 31707858 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking with simultaneous intrastromal corneal ring segment implantation
Number of subjects: 30
Study 31707858 — intervention group
Group type: COMPARATOR
Intervention: Corneal collagen cross-linking alone
Number of subjects: 30
Study 30835744 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Specific Functional Scale (PSFS)
Number of subjects: 86
Study 30463770 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cholecystostomy (PC)
Number of subjects: 145
Study 30463770 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval cholecystectomy (CCY)
Number of subjects: 145
Study 26715577 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (Cu) plus ascorbic acid (AA) at 4/1 Cu/Fe molar ratio
Number of subjects: 14
Study 26715577 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (Cu) plus ascorbic acid (AA) at 6/1 Cu/Fe molar ratio
Number of subjects: 14
Study 26715577 — intervention group
Group type: COMPARATOR
Intervention: Iron alone (Control)
Number of subjects: 14
Study 26715577 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper (Cu) plus ascorbic acid (AA) at 8/1 Cu/Fe molar ratio
Number of subjects: 14
Study 24559810 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger powder supplementation (3 one-gram capsules daily for 8 weeks)
Number of subjects: 88
Study 24559810 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 one-gram microcrystalline-containing capsules daily for 8 weeks)
Number of subjects: 88
Study 22934442 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 22934442 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 0
Study 20004278 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer alone
Number of subjects: 194
Study 20004278 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer/SLS
Number of subjects: 194
Study 20004278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study 17921390 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg Zn/d as a supplement
Number of subjects: 142
Study 17921390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 16173138 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (12.5 mmol daily for 6 weeks)
Number of subjects: 59
Study 16173138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 16173138 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone treatment
Number of subjects: 59
Study 12549635 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 104
Study 12549635 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (without Tamsulosin)
Number of subjects: 104
Study 10553163 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐3 (10 microg/kg/day, s.c., day 1‐5) followed by G‐CSF (5 microg/kg/day, day 6‐8)
Number of subjects: 50
Study 10553163 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐3 (10 microg/kg/day, s.c., day 1‐5) followed by GM‐CSF (5 microg/kg/day, day 6‐8)
Number of subjects: 50
Study 10553163 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐3+G‐CSF
Number of subjects: 50
Study 10553163 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐3+GM‐CSF
Number of subjects: 50
Study 8821120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study 8821120 — intervention group
Group type: COMPARATOR
Intervention: Blackcurrant oil supplementation
Number of subjects: 0
Study 31117905 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 62
Study 31117905 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone
Number of subjects: 62
Study 31117905 — intervention group
Group type: EXPERIMENTAL
Intervention: History of moderate to severe TBI
Number of subjects: 62
Study 31117905 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD status
Number of subjects: 62
Study 29324430 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable, high-fluid capacity underpad
Number of subjects: 40
Study 29324430 — intervention group
Group type: COMPARATOR
Intervention: Nonpermeable, reusable containment products
Number of subjects: 40
Study 26474174 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus icotinib (125 mg thrice daily for 4-8 months)
Number of subjects: 41
Study 26474174 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 41
Study 23577773 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal stimulation
Number of subjects: 44
Study 23577773 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold stimulation
Number of subjects: 44
Study 23577773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency stimulation
Number of subjects: 44
Study 23577773 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard stimulation
Number of subjects: 44
Study 23577773 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent system placement
Number of subjects: 44
Study 21263367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent propofol sedation (bolus of 2-4 mg/kg, followed by repeat boluses of 0.5-2 mg/kg/dose as needed)
Number of subjects: 170
Study 21263367 — intervention group
Group type: COMPARATOR
Intervention: Continuous propofol sedation (bolus of 2-4 mg/kg, followed by continuous infusion of 100 μg/kg/min with 1-mg/kg/dose boluses)
Number of subjects: 170
Study 21263367 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intermittent and continuous)
Number of subjects: 170
Study 19100061 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in DCM patients
Number of subjects: 90
Study 19100061 — intervention group
Group type: COMPARATOR
Intervention: Coxsackievirus binding domain (exon 4) of Adenovirus receptor (CAR) in healthy adults
Number of subjects: 90
Study 15790932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 0
Study 15790932 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestimide
Number of subjects: 0
Study 15790932 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12883406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil effect site concentration of 0.5 ng/ml (group 1)
Number of subjects: 110
Study 12883406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil effect site concentration of 1.25 ng/ml (group 4)
Number of subjects: 110
Study 12883406 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol concentration adjusted based on BIS values
Number of subjects: 110
Study 12883406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil concentrations
Number of subjects: 110
Study 12883406 — intervention group
Group type: COMPARATOR
Intervention: Mean arterial pressure, heart rate, time to tracheal extubation, awareness, satisfaction scores, morphine requirements
Number of subjects: 110
Study 10786240 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 0
Study 10786240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of schizophrenic patients
Number of subjects: 0
Study 10786240 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 8874444 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser iridotomy in one eye
Number of subjects: 21
Study 8874444 — intervention group
Group type: COMPARATOR
Intervention: No intervention in the fellow eye (control)
Number of subjects: 21
Study 2054278 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 12
Study 2054278 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 4 mg with paracetamol 650 mg
Number of subjects: 12
Study 2054278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6393937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin
Number of subjects: 0
Study 6393937 — intervention group
Group type: COMPARATOR
Intervention: Rectal metronidazole
Number of subjects: 0
Study 31303389 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure on four different acupoints plus standard care
Number of subjects: 100
Study 31303389 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 29384326 — intervention group
Group type: EXPERIMENTAL
Intervention: 75‐g 2‐h oral glucose tolerance test (OGTT)
Number of subjects: 4959
Study 29384326 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced maternal age
Number of subjects: 4959
Study 29384326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy body mass index (overweight)
Number of subjects: 4959
Study 29384326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy body mass index (obesity)
Number of subjects: 4959
Study 29384326 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal history of diabetes
Number of subjects: 4959
Study 29384326 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal history of diabetes
Number of subjects: 4959
Study 27102653 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program
Number of subjects: 1440
Study 25197908 — intervention group
Group type: EXPERIMENTAL
Intervention: Real ear acupressure (EAP) treatment
Number of subjects: 245
Study 25197908 — intervention group
Group type: COMPARATOR
Intervention: Sham ear acupressure (EAP) treatment
Number of subjects: 245
Study 22697191 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 127
Study 22697191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 21187618 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine solution
Number of subjects: 40
Study 21187618 — intervention group
Group type: COMPARATOR
Intervention: 5.25% sodium hypochlorite solution
Number of subjects: 40
Study 18776075 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring-based care
Number of subjects: 57
Study 18776075 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 57
Study 16550876 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastic with anesthetic (sodium hyaluronate 1.5% and lidocaine 1%)
Number of subjects: 874
Study 16550876 — intervention group
Group type: COMPARATOR
Intervention: Viscoelastic without anesthetic
Number of subjects: 874
Study 12208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (500 mg twice daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Number of subjects: 325
Study 12208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily), metronidazole (400 mg twice daily), and omeprazole (20 mg twice daily)
Number of subjects: 325
Study 12208796 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (both regimens)
Number of subjects: 325
Study 12208796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 10512922 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of small (<3 mm) basal ganglia lesions
Number of subjects: 3660
Study 10512922 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter grade
Number of subjects: 3660
Study 10512922 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models controlling for non-MRI variables and severity of white matter lesions
Number of subjects: 3660
Study 7851677 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 260
Study 7851677 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 260
Study 1823064 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (6 micrograms/kg)
Number of subjects: 20
Study 1823064 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine injection (5 minutes before pentagastrin)
Number of subjects: 20
Study 1823064 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine injection (1 hour before pentagastrin)
Number of subjects: 20
Study 1823064 — intervention group
Group type: COMPARATOR
Intervention: Sham feeding
Number of subjects: 20
Study 1823064 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oral intake of ranitidine
Number of subjects: 20
Study 7274006 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 0
Study 7274006 — intervention group
Group type: COMPARATOR
Intervention: Placebo (bed rest)
Number of subjects: 0
Study 31432689 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib-based therapy
Number of subjects: 271
Study 30118784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen (NCK) Program, 6-week duration, 3 hours weekly, including hands-on cooking classes and a food market visit
Number of subjects: 76
Study 30118784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and Culinary in the Kitchen (NCK) Program
Number of subjects: 76
Study 30118784 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 76
Study 26952222 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine infusion at a rate of 1.5mg/kg/min
Number of subjects: 60
Study 26952222 — intervention group
Group type: COMPARATOR
Intervention: IV esmolol infusion at a rate of 1mg/kg/min
Number of subjects: 60
Study 25223462 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 371
Study 25223462 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 371
Study 22294563 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-PACK programme (nurse delivered falls prevention programme)
Number of subjects: 16000
Study 22294563 — intervention group
Group type: COMPARATOR
Intervention: Usual care practice (control group)
Number of subjects: 16000
Study 20388562 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial rectal wall advancement flap (Group I)
Number of subjects: 40
Study 20388562 — intervention group
Group type: COMPARATOR
Intervention: Mucosal advancement flap (Group II)
Number of subjects: 40
Study 18821872 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for alcohol dependence (details on specific medications or behavioral interventions not provided)
Number of subjects: 1383
Study 18821872 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for alcohol dependence
Number of subjects: 1383
Study 16763371 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary proteomic analysis using SELDI‐MS
Number of subjects: 42
Study 16763371 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of patients as SSNS or SRNS
Number of subjects: 42
Study 16763371 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of a protein of mass 4,144 daltons
Number of subjects: 42
Study 16763371 — intervention group
Group type: EXPERIMENTAL
Intervention: SELDI‐MS combined with bioinformatics
Number of subjects: 42
Study 12795130 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extradural infusion of bupivacaine
Number of subjects: 10
Study 12795130 — intervention group
Group type: COMPARATOR
Intervention: Continuous extradural infusion of morphine
Number of subjects: 10
Study 10563213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 0
Study 10563213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8733681 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 58
Study 8733681 — intervention group
Group type: COMPARATOR
Intervention: Control (standard anti-emetics)
Number of subjects: 58
Study 1761451 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 65
Study 1761451 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 65
Study 6349743 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of emepronium bromide and flavoxate hydrochloride
Number of subjects: 20
Study 6349743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30419226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg, 3 times daily, started 4 hours before the ascent)
Number of subjects: 92
Study 30419226 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide (125 mg, twice daily, started the night before the ascent)
Number of subjects: 92
Study 30419226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 92
Study 30419226 — intervention group
Group type: COMPARATOR
Intervention: Acetazolamide
Number of subjects: 92
Study 30206346 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid intake (two-thirds of normal intake)
Number of subjects: 80
Study 30206346 — intervention group
Group type: COMPARATOR
Intervention: Normal fluid intake
Number of subjects: 80
Study 30206346 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid intake
Number of subjects: 80
Study 28462933 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy (group‐CBT) added to standard spinal cord injury inpatient rehabilitation (SR)
Number of subjects: 50
Study 28462933 — intervention group
Group type: COMPARATOR
Intervention: Standard spinal cord injury inpatient rehabilitation (SR) without group‐CBT
Number of subjects: 50
Study 25613747 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous GIP (4 pmol/kg/min)
Number of subjects: 20
Study 22447467 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan, 12 mg monotherapy (group A)
Number of subjects: 26
Study 22447467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ), 6.25 mg in combination with candesartan, 8 mg (group B)
Number of subjects: 26
Study 20933098 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI group (n = 258)
Number of subjects: 464
Study 20933098 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 206)
Number of subjects: 464
Study 19000959 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine group (TmG) - patient-GP short-messages-based interaction
Number of subjects: 285
Study 16998171 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patches (6-week reducing dose regimen)
Number of subjects: 98
Study 16998171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 14587237 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite analysis using LOH/MSI in exfoliated cells from urinary sediment
Number of subjects: 160
Study 14587237 — intervention group
Group type: COMPARATOR
Intervention: Urinary cytology
Number of subjects: 160
Study 14587237 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite alterations in superficial tumors
Number of subjects: 160
Study 14587237 — intervention group
Group type: EXPERIMENTAL
Intervention: D4S243 microsatellite marker
Number of subjects: 160
Study 11898235 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise during chemotherapy
Number of subjects: 78
Study 11898235 — intervention group
Group type: COMPARATOR
Intervention: Non-exercisers (control group)
Number of subjects: 78
Study 9366671 — intervention group
Group type: EXPERIMENTAL
Intervention: Optic neuritis
Number of subjects: 0
Study 9366671 — intervention group
Group type: COMPARATOR
Intervention: Anterior ischemic optic neuropathy
Number of subjects: 0
Study 8466240 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein restricted diet (0.8‐1.1 g/kg/day)
Number of subjects: 56
Study 8466240 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 4003187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 4003187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29106669 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette ads with high youth appeal
Number of subjects: 417
Study 29106669 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarette ads with low youth appeal
Number of subjects: 417
Study 29106669 — intervention group
Group type: COMPARATOR
Intervention: Control ads
Number of subjects: 417
Study 26847219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 171
Study 26847219 — intervention group
Group type: COMPARATOR
Intervention: Control (no hypnosis)
Number of subjects: 171
Study 25667123 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium distillate solution (15 mL gargled 4 times a day for 14 days)
Number of subjects: 56
Study 25667123 — intervention group
Group type: COMPARATOR
Intervention: Routine solution (15 mL gargled 4 times a day for 14 days)
Number of subjects: 56
Study 22141591 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin plus common sedation and analgesia (atropine, fentanyl, vecuronium)
Number of subjects: 60
Study 22141591 — intervention group
Group type: COMPARATOR
Intervention: Common sedation and analgesia (atropine, fentanyl, vecuronium)
Number of subjects: 60
Study 20354490 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab plus a sirolimus coated stent
Number of subjects: 60
Study 20354490 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab plus a bare stent
Number of subjects: 60
Study 20354490 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab plus PTA
Number of subjects: 60